Obsidian Therapeutics details director stock options

Obsidian Therapeutics director Heidi Hagen reported existing stock option holdings in connection with becoming an insider.

Rhea-AI Filing Summary

Obsidian Therapeutics director Heidi Hagen reported existing stock option holdings in connection with becoming an insider. The holdings include two options to purchase Obsidian common stock at an exercise price of $0.78 per share. One option covers 180,000 underlying shares, is fully vested and exercisable, and expires on November 30, 2031. The second option covers 337,500 underlying shares, expires on June 24, 2034, and vests in 16 equal quarterly installments beginning after June 25, 2024, contingent on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hagen Heidi

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F2	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 517,500 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying this option are fully vested and exercisable.
2. F2. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Exercise price: $0.78 per share Underlying shares (fully vested option): 180,000 shares Underlying shares (installment vesting option): 337,500 shares +3 more

6 metrics

Exercise price $0.78 per share Exercise price for both reported stock options

Underlying shares (fully vested option) 180,000 shares Common stock underlying option expiring November 30, 2031

Underlying shares (installment vesting option) 337,500 shares Common stock underlying option expiring June 24, 2034

Vesting installments 16 installments Second option vests in sixteen equal quarterly installments after June 25, 2024

Option expiration (first grant) November 30, 2031 Expiration date of fully vested stock option

Option expiration (second grant) June 24, 2034 Expiration date of option vesting quarterly

Key Terms

Stock Option (Right to Buy), fully vested and exercisable, quarterly installments, underlying security shares

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

fully vested and exercisable financial

"The shares underlying this option are fully vested and exercisable."

quarterly installments financial

"shares underlying this option vest in sixteen (16) equal quarterly installments"

underlying security shares financial

"underlying_security_shares: "337500.0000""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Obsidian Therapeutics (OBX) disclose in Heidi Hagen’s Form 3?

Obsidian Therapeutics reported that director Heidi Hagen holds two stock options to buy common stock at $0.78 per share, covering 517,500 underlying shares in total, with specified vesting schedules and expiration dates.

How many Obsidian Therapeutics (OBX) shares are covered by Heidi Hagen’s vested option?

One option held by Heidi Hagen covers 180,000 underlying shares of Obsidian common stock. Footnotes state these shares are fully vested and exercisable, with the option expiring on November 30, 2031.

What are the terms of Heidi Hagen’s second stock option at Obsidian Therapeutics (OBX)?

The second option covers 337,500 underlying common shares at an exercise price of $0.78 per share. It expires on June 24, 2034 and vests in 16 equal quarterly installments starting after June 25, 2024, subject to continued service.

Does the Form 3 for Obsidian Therapeutics (OBX) show any stock purchases or sales by Heidi Hagen?

No purchases or sales are reported. The Form 3 lists existing stock option holdings and their terms only, with no transaction codes indicating buys, sells, or exercises on the reported date.

What is the exercise price of Heidi Hagen’s Obsidian Therapeutics (OBX) stock options?

Both reported stock options have an exercise price of $0.78 per share for Obsidian common stock. This price applies to the option covering 180,000 shares and the option covering 337,500 shares, as disclosed in the filing data.

When do Heidi Hagen’s Obsidian Therapeutics (OBX) stock options expire?

One option held by Heidi Hagen expires on November 30, 2031. The other option expires on June 24, 2034. Both expiration dates are specified for the respective stock option grants reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 07:10 PM Accepted by SEC EDGAR 08/03/2026 - 06:37 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hagen Heidi

(Last) (First) (Middle)

OBSIDIAN THERAPEUTICS, INC.

1030 MASSACHUSETTS AVE

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026

3. Issuer Name and Ticker or Trading Symbol
Obsidian Therapeutics, Inc. [ OBX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	11/30/2031	Common Stock	180,000	$0.78	D
Stock Option (Right to Buy)	(2)	06/24/2034	Common Stock	337,500	$0.78	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable.

2. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Gabriela Morales-Rivera, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)